Real-World Experiences With Aflibercept 8mg

EP: 1.Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME

EP: 2.Choosing First-Line Therapy in nAMD or DME

EP: 3.When to Switch to More Efficacious Agents

EP: 4.Real-World Experiences With Faricimab

Now Viewing

EP: 5.Real-World Experiences With Aflibercept 8mg

EP: 6.Efficacy and Durability: New Therapies vs Aflibercept 2mg

EP: 7.Perspectives on Retinal Fluid Management

EP: 8.Perspectives on Loading Dose Recommendations for New Therapies

EP: 9.Safety Considerations for New Therapies

EP: 10.The Impact of Biosimilars in Retinal Diseases

EP: 11.The Status of Gene Therapy Development for Retinal Diseases

EP: 12.Considering Safety of Gene Therapy for Retinal Diseases

EP: 13.Role of Tyrosine Kinase Inhibitors and Gene Therapy in Retinal Diseases

EP: 14.Perspectives on the Future of Retinal Disease Management

Summary

Experts discuss their experiences with aflibercept 8 mg in the real world. Diana Do, MD mentions that, as an early adopter, she has started using aflibercept 8 mg in both treatment-naive and treatment-experienced patients. She notes a spectrum of responses, with some patients showing significant improvements in vision and reductions in retinal thickness, while others, particularly those with challenging, previously treated eyes, may still need closer follow-up. Kenny Fan, MD, MBA agrees with her, and emphasizes how aflibercept 8 milligrams will be used in a larger patient population with larger lesions, prior experience with other medications, and various comorbidities. He mentions that most of his patients on aflibercept 8 mg are in the Medicare population with neovascular age-related macular edema (nAMD), and he has been generally pleased with the results. However, he acknowledges the need for more data collection in the real-world setting, especially concerning the label extension after the initial three-month injections.

This summary was AI-generated and edited for clarity.